NC Testing in LC & POTS

Sponsor
University of Calgary (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05914649
Collaborator
(none)
50
1
54.5

Study Details

Study Description

Brief Summary

Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction. The investigators will test the hypothesis that IV saline will improve cognitive function in patients with POTS and Long COVID, compared to their baseline scores.

Condition or Disease Intervention/Treatment Phase
  • Other: IV normal saline (1 Litre)
N/A

Detailed Description

Many POTS patients report cognitive dysfunction, otherwise referred to as brain fog, mental fog, mental clouding, or mental fatigue. Importantly, this cognitive dysfunction can occur even while lying down or seated, limiting ability to engage in work and educational activities. Despite the prevalence and clinical impact of cognitive dysfunction in POTS, there are limited studies examining this phenomenon. Many patients with post acute sequelae of SARS- COV-2 (PASC, or "Long COVID") experience symptoms such as subjective cognitive impairment, ("brain fog"), fatigue, memory loss, headache, and fluctuation of blood pressure amongst other signs and symptoms. This study will measure cognitive function in patients with POTS and Long COVID, compared to healthy controls. This study will also evaluate IV normal saline as a potential treatment for reduced cognitive function in POTS and Long COVID.

The findings from this study will be an initial first step towards understanding any neurocognitive impairment in participants with long COVID and POTS patients. This is a critical first step to future studies to assess underlying pathophysiology and potential treatments.

Primary hypothesis: Some objective measures of neurocognitive functions will improve in Long COVID and POTS patients after the infusion of normal saline.

The primary analysis will be the standing 5RTI task on the CANTAB testing between patients (POTS and long COVID) before and after the saline infusion.

Study Day and Instrumentation:
  • A trained research staff member will insert an intravenous line in the vein of the participant's arm to give 1 liter of normal saline which can take up to 60 minutes. The normal saline will be given in between the two CANTAB tests.

  • After instrumentation, participant will lie supine for at least 10 minutes while their ECG & BP are continuously recorded.

  • The participant will stand up quickly (within several seconds), and then stand quietly for about 11 minutes while recording continues. The lying-> stand will allow us to assess for hemodynamics of IST, POTS & OH. Any time during the test, they want to sit down a chair will be provided to them.

  • After the stand test, participant will be asked to do the Trail Making Test (TMT) in the standing position. They will be asked to join numbers and letters in a circle. This test should not take more than approximately 10 minutes and will be performed twice before and after the normal saline infusion. Any time during the test, they want to sit down a chair will be provided to them.

  • The participant will then be seated comfortably in a chair with their feet on the floor. They will be asked to do the Heart Counting Task (HCT) test. The participant will be asked to count their heartbeats without using their hands or other means to feel pulse that might affect their performance. This test will also be performed twice before and after the normal saline infusion and will approximately take around 10 minutes each time.

  • The research team will then de instrument the participant except for the Blood Pressure cuff on the arm. The research team will continue to monitor the blood pressure throughout the study.

  • Neuropsychological testing of the cognitive domains of memory, attention and executive function will be assessed using the Cambridge Neuropsychological Test Automated Battery (CANTAB) both seated and standing twice.

  • The seated cognitive testing period will last approximately 60 minutes.

  • The participant will be asked to stand unaided for up to 30 minutes and repeat portions of the CANTAB tests. Blood Pressure will be monitored throughout the stand test. A chair will be provided to the participant in case they would want to sit down.

  • At the end of each stand test, the research team will assess patient symptoms using the Vanderbilt Orthostatic Symptoms Score (VOSS). VOSS is a 9-item symptom-rating with each item score from 0-10 (worst) for a total score ranging from 0-90.

  • Normal Saline will be infused intravenously which can take up to 60 minutes. Normal Saline will be given by a trained research staff member.

  • The research team will instrument the participant again and will repeat the supine, stand and the cognitive tests (TMT & HCT).

  • After that the cognitive testing on the CANTAB will be repeated for both sitting and standing and the research team will again assess the participant's symptoms using the VOSS score. Repeating these tests will help the research team in assessing if with the infusion of normal saline, the cognitive functions will improve for the Long COVID and POTS patients.

  • The study will then be finished. The research team will remove the recording patches and electrodes.

CANTAB Testing Protocol: CANTAB tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control. The subtests that will be used in this study for seated cognitive function are: Reaction Time Test (psychomotor Speed), Rapid Visual Information processing (Attention), Paired Associates Learning (Visual Episodic Memory), Spatial Span (Working memory), Verbal Recognition Memory (Verbal memory), Multitasking Test (Executive Function - Inhibition), Stocking of Cambridge (Executive Function - Planning) and the Emotional Bias Task (Emotion Processing). All tests are administered using a touch screen tablet, participants will respond to each test on-screen. Standardized written and audio instructions are given to participants through the software, and practice trials are completed before each test, reducing practice effects.

After the in-lab portion of the study, participants will complete a series of validated questionnaires through a paper or RedCap secure web application for assessment of psychiatric symptoms. A unique URL link will be sent to the participants via Redcap Survey. These online surveys will take ~60 minutes to complete.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Neurocognitive Testing in Long COVID and Postural Tachycardia Syndrome Patients With Normal Saline: A Pilot Study
Anticipated Study Start Date :
Jun 15, 2023
Anticipated Primary Completion Date :
Dec 31, 2026
Anticipated Study Completion Date :
Dec 31, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Normal Saline

1 Liter of normal saline infused intravenously

Other: IV normal saline (1 Litre)
One Liter of IV normal saline will be infused intravenously

Outcome Measures

Primary Outcome Measures

  1. 5RTI Reaction Time task (Standing) [During Procedure (3 hours)]

    5RTI Reaction Time Score (Standing) before IV saline compared to 5RTI score after IV saline measured in milliseconds (ms). The minimum score is 100 ms and the maximum score is 5100 ms. A longer time is a worse outcome.

Secondary Outcome Measures

  1. Reaction Time Test (Psychomotor Speed) [During Procedure (3 hours)]

    Reaction Time Test score before IV saline compared to after IV saline measured in milliseconds. The minimum score is 100 ms and the maximum score is 5100 ms. A longer time is a worse outcome.

  2. Paired Associates Learning (Visual Episodic Memory) [During Procedure (3 hours)]

    Paired Associates Learning score before IV saline compared to after IV saline measured in arbitrary units. The minimum score is 0 and the maximum score is 70. A higher score is a worse outcome.

  3. Verbal Recognition Memory (Verbal memory) [During Procedure (3 hours)]

    Verbal Recognition Memory test score before IV saline compared to after IV saline. The range is 0-18. A higher score is a better outcome.

  4. Multitasking Test (Executive Function - Inhibition) [During Procedure (3 hours)]

    Multitasking Test Time before IV saline compared to after IV saline measured in ms. The range is 100 - 2000 ms. A longer time is a worse is a worse outcome.

Other Outcome Measures

  1. Sitting heart rate [During Procedure (10 minutes)]

    Sitting heart rate before IV saline compared to after IV saline.

  2. Standing heart rate [During Procedure (10 minutes)]

    Standing heart rate before IV saline compared to after IV saline.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients with diagnosis of Long COVID

  • SARS-COV2 test positive

  • Symptoms > 12 weeks post COVID

  • Subjective complaint of 'brain fog" or cognitive dysfunction

  • Patients with diagnosis of Postural Orthostatic Syndrome (POTS) from the Calgary Autonomic Investigation and Management Clinic

  • Subjective complaint of 'brain fog" or cognitive impairment

  • Healthy participants

  • Without POTS or "brain fog"

  • Age 18 to 60 years

  • Female and Male

  • Able to give an informed consent

Exclusion Criteria:
  • Patients with overt causes for POTS (e.g., dehydration, prolonged bed rest)

  • An inability to safely withdraw from medicine(s) that could make test interpretation difficult and impossible.

  • Other factors which are in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule.

  • Unable to give an informed consent.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Calgary

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Calgary
ClinicalTrials.gov Identifier:
NCT05914649
Other Study ID Numbers:
  • REB23-0202
First Posted:
Jun 22, 2023
Last Update Posted:
Jun 26, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Calgary
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 26, 2023